8 / 14
Tissue Science 2019
June 17-18, 2019
London, UK
Advances in Tissue
Engineering and
Biomaterials Science
13
th
Edition of International Conference on
Journal of Biomedical Sciences
ISSN: 2254-609X
Page 36
J Biomedical Sci 2019, Volume 08
Stem cell therapy for the treatment of severe tissue damage
after radiation exposure
A Chapel
1
, A Semont
1
, N Mathieu
1
, C Linard
1
, L Douay
2
, NC Gorin
2
, M Mothy
2
,
JM Simmon
3
, H Rouard
2
, JJ Lataillade
4
, J Voswinkel
3
,
and
M Benderitter
1
1
Institute of Radiological Protection and Nuclear Safety, France
2
Saint Antoine Hospital APHP and UPMC University, France
3
Pitie-Salpetriere University Hospital, France
4
Percy Military Hospital, France
T
he late adverse effects of pelvic radiotherapy concern
5 to 10% of them, which could be life threatening.
However, a clear medical consensus concerning the
clinical management of such healthy tissue sequelae
does not exist. Our group has demonstrated in preclinical
animal models that systemic MSC injection is a promise
approach for themedicalmanagement of gastrointestinal
disorder after irradiation. We have shown that MSC
migrate to damaged tissues and restore gut functions
after irradiation.
The clinical status of four first patients suffering from
severe pelvic side effects resulting from an over-dosage
was improved following MSC injection in a compassional
situation. A quantity of 2x106 - 6x106 MSC /kg were
infused intravenously to the patients. Pain, hemorrhage,
frequency of diarrheas and fistulisation as well as the
lymphocyte subsets in peripheral blood were evaluated
before MSC therapy and during the follow-up. Two
patients revealed a substantiated clinical response
for pain and hemorrhage after MSC therapy. In one
patient pain reappeared after 6 months and again
substantially responded on a second MSC infusion. A
beginning fistulisation process could be stopped in one
patient resulting in a stable remission for more than 3
years of follow-up. The frequency of painful diarrhea
diminished from an average of 6/d to 3/d after the first
and 2/d after the 2nd MSC injection in one patient. In all
patients, prostate cancer remained in stable complete
remission. A modulation of the lymphocyte subsets
towards a regulatory pattern and diminution of activated
T cells accompanies the clinical response in refractory
irradiation-induced colitis. No toxicity occurred.
MSC therapy was safe and effective on pain, diarrhea,
haemorrhage, inflammation, fibrosis and limited
fistulisation. For patients with refractory chronic
inflammatory and fistulising bowel diseases, systemic
MSC injections represent a safe option for salvage
therapy. A clinical phase II trial will start in 2017
alain.chapel@irsn.fr